OTTAWA, Dec. 11, 2017 /CNW/ - The Patented Medicine Prices Review Board (PMPRB) today published a scoping paper which providesits initial thoughts on how best to operationalize the Minister of Health's proposed amendments to the Patented Medicines Regulations, which were published in the Canada Gazette, Part I on December 2, 2017.
This document, which is intended to be read in conjunction with the proposed amendments and the accompanying Regulatory Impact Analysis Statement, will enable an open and informed dialogue with stakeholders on areas of the PMPRB's drug pricing guidelines in need of reform as a result of the amendments and changes to the pharmaceutical environment in Canada.
In the coming weeks, Health Canada and the PMPRB will be hosting information sessions on the proposed amendments and the scoping paper. The PMPRB will also be making Guideline reform the focus of its upcoming annual outreach sessions for patentees to be held in January 2018. It is expected that a first draft of the PMPRB's new Guidelines will be made public in the spring of 2018, to be followed by technical roundtables with stakeholders and interested members of the public.
It is hoped that this document will serve as a catalyst for a more informed, focussed and productive consultation process on framework modernization, with a view to having new Guidelines in place by early 2019.
These changes, which are an integral part of the Government of Canada's commitment to improve affordability and accessibility of pharmaceuticals, will come into force in early 2019.
Follow us on Twitter: @PMPRB_CEPMB
SOURCE Patented Medicine Prices Review Board
Subscribe to our Free Newsletters!
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...
Water is essential to balance body fluids, boost brain function, improve digestion, prevent ...
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...View All